Daniel Zlotoff, MD
Advanced Heart Failure and Transplant Cardiology · Boston, MANPI 1780943803
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $96,400 of the $96,472 with a category attached, or 99.9%. E.r. Squibb & Sons, L.L.C. accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Among advanced heart failure and transplant cardiology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 8 payments — averaging $12,059 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$96K
- Abbott$43
- Merck$29
What the payments were for
- Consulting fees$96,400100%
- Food & beverage$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $96,400 |
| Abbott | 2 | $43 |
| Merck | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$96,400
How this compares
$96,472 in reported general payments places this provider in the 90th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.
See all advanced heart failure and transplant cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 98 | $168,952 |
| JardianceEmpagliflozin | 80 | $121,638 |
| FarxigaDapagliflozin Propanediol | 59 | $87,604 |
| EliquisApixaban | 63 | $66,573 |
| VascepaIcosapent Ethyl | 11 | $3,835 |
| Metoprolol Succinate | 99 | $1,974 |
| Atorvastatin Calcium | 110 | $1,299 |
| Rosuvastatin Calcium | 14 | $973 |
| Ezetimibe | 26 | $782 |
| Torsemide | 23 | $660 |
| Losartan Potassium | 59 | $628 |
| Spironolactone | 99 | $535 |
| Carvedilol | 24 | $231 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $194 |
| Amlodipine Besylate | 15 | $112 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Boston
- Pablo Quintero PinzonBoston$137K
- Christina Vander PluymBoston$55K
- Monica AhluwaliaBoston$39K
- Stephanie MooreBoston$30K
- David DenofrioBoston$18K
- Robb KociolBoston$12K
- Marwa SabeBoston$12K
- Edward GrandinBoston$8K
- Kemar BrownBoston$7K
- Kevin DalyBoston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.